2,750 Shares in Bio-Rad Laboratories, Inc. $BIO Acquired by Nano Cap New Millennium Growth Fund L P

Nano Cap New Millennium Growth Fund L P bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,750 shares of the medical research company’s stock, valued at approximately $833,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. UMB Bank n.a. boosted its holdings in Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after purchasing an additional 40 shares during the last quarter. CWM LLC boosted its holdings in Bio-Rad Laboratories by 26.7% in the fourth quarter. CWM LLC now owns 256 shares of the medical research company’s stock worth $78,000 after purchasing an additional 54 shares during the last quarter. OneDigital Investment Advisors LLC boosted its holdings in Bio-Rad Laboratories by 1.9% in the third quarter. OneDigital Investment Advisors LLC now owns 2,954 shares of the medical research company’s stock worth $828,000 after purchasing an additional 55 shares during the last quarter. RK Asset Management LLC boosted its holdings in Bio-Rad Laboratories by 0.5% in the fourth quarter. RK Asset Management LLC now owns 14,573 shares of the medical research company’s stock worth $4,415,000 after purchasing an additional 71 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $375.00 to $300.00 in a report on Tuesday, April 7th. Royal Bank Of Canada assumed coverage on shares of Bio-Rad Laboratories in a report on Friday, May 15th. They issued an “outperform” rating and a $320.00 target price on the stock. Weiss Ratings cut shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Wells Fargo & Company dropped their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $303.33.

Bio-Rad Laboratories Stock Down 0.1%

Shares of BIO stock opened at $287.49 on Friday. The company has a market capitalization of $7.69 billion, a price-to-earnings ratio of 47.36 and a beta of 1.06. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $343.12. The company’s fifty day moving average price is $274.24 and its 200-day moving average price is $292.33. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 EPS for the quarter, missing the consensus estimate of $1.97 by ($0.08). The firm had revenue of $592.10 million for the quarter, compared to the consensus estimate of $589.91 million. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.54 earnings per share. Sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.32 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.